Rating Change
Baird reiterated its Outperform rating on Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) on August 19, 2026.
reiterateNASDAQ:AMLX
Baird Reiterates Outperform Rating on Amylyx Pharmaceuticals, Inc. (AMLX)
Baird reiterated its Outperform rating on Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) on August 19, 2026.
At publication ·
What changed
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) · reiterate
- Firm
- Baird
- Rating
- Outperform to Outperform
- Price at event
- $38.60
- Market capitalization
- $1.3B
At a glance
Key takeaways
- Baird reiterated an Outperform rating on Amylyx Pharmaceuticals (AMLX) on August 19, 2026, with the stock trading at $38.60 and a market capitalization of $1.3 billion.
Market Context
Amylyx Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $38.60 with a market capitalization of $1.3B.
Analyst coverage from Baird provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Amylyx Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Amylyx Pharmaceuticals, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 19, 2026 | Mizuho | Outperform | N/A |
| Aug 19, 2026 | Guggenheim | Buy | N/A |
| Aug 19, 2026 | Baird | Outperform | N/A |
| Aug 18, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 17, 2026 | Mizuho | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View AMLX Stock Page
Frequently Asked Questions
What does the Outperform rating mean for AMLX?
A rating of Outperform from Baird reflects the analyst's outlook on Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the AMLX forecast page.